CYNATA THERAPEUTICS LIMITED - Announcements

8.82%

18.5¢

Market Cap $41.80M

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Announcements

Filter Results

All Price Sensitive Only

CYP	Cynata to Increase Exposure in Japan	PRICE SENSITIVE	09/10/17	208.86KB	Share
CYP	US Patent Granted for Cynata Cymerus Technology	PRICE SENSITIVE	27/09/17	178.12KB	Share
CYP	HC Wainwright & Co Updates Cynata Research Coverage		11/09/17	158.18KB	Share
CYP	Cynata to Present at Rodman & Renshaw Investor Conference		05/09/17	162.42KB	Share
CYP	Health Canada Meeting Advances CYP Global Development Plans	PRICE SENSITIVE	31/08/17	165.95KB	Share
CYP	Appendix 4G		24/08/17	174.24KB	Share
CYP	Appendix 4E & Financial Statements	PRICE SENSITIVE	24/08/17	1005.24KB	Share
CYP	Positive Data from CYP MSCs in 2nd Preclinical Asthma Study	PRICE SENSITIVE	23/08/17	226.69KB	Share
CYP	Appendix 3B		07/08/17	266.57KB	Share
CYP	June 2017 Quarterly Report	PRICE SENSITIVE	28/07/17	283.27KB	Share
CYP	NDF's Stuart Roberts Initiates Cynata Research Coverage		24/07/17	157.69KB	Share
CYP	FDA Meeting Provides Clear Path for US Development Plans	PRICE SENSITIVE	05/07/17	168.09KB	Share
CYP	Change of Address		04/07/17	117.52KB	Share
CYP	Cynata Therapeutics GvHD Clinical Trial & Corporate Progress	PRICE SENSITIVE	27/06/17	177.28KB	Share
CYP	CYP MSC Data in Asthma Model Published in Sceintific Journal	PRICE SENSITIVE	22/06/17	230.33KB	Share
CYP	Cynata Files New Patent Application for Cymerus in Oncology	PRICE SENSITIVE	20/06/17	186.95KB	Share
CYP	United States Patent for Core Cynata Technology	PRICE SENSITIVE	19/06/17	179.58KB	Share
CYP	Van Leeuwenhoeck Institute Initiates CYP Research Coverage		07/06/17	159.1KB	Share
CYP	Appendix 3Y-Peter Webse		02/06/17	24.34KB	Share
CYP	Appendix 3Y Lodged 26 May 2017-Date Correction		02/06/17	24.08KB	Share
CYP	Cynata Investor Presentation May 2017		29/05/17	874.26KB	Share
CYP	Appendix 3Y-Paul Wotton		26/05/17	24.02KB	Share
CYP	Appendix 3Y-John Chiplin		17/05/17	23.36KB	Share
CYP	Treatment Commences in Cynata's World First Clinical Trial	PRICE SENSITIVE	16/05/17	209.68KB	Share
CYP	Trading Halt	PRICE SENSITIVE	15/05/17	191.19KB	Share
CYP	Interview with UK Chief Investigator in CYP Clinical Trial		10/05/17	163.88KB	Share
CYP	Shaw & Partners Initiates Cynata Research Coverage		08/05/17	155.98KB	Share
CYP	Appendix 3Y-Paul Wotton		08/05/17	24.13KB	Share
CYP	Cyanta Presentation & Webcast		04/05/17	163.08KB	Share
CYP	Appendix 3Y-Stewart Washer		03/05/17	24.51KB	Share
CYP	March 2017 Quarterly Report	PRICE SENSITIVE	26/04/17	306.13KB	Share
CYP	Cynata Advances to Pre-IND Meeting with US FDA	PRICE SENSITIVE	19/04/17	168.35KB	Share
CYP	CYP Files for New Patent for Oncology Applications	PRICE SENSITIVE	12/04/17	163.15KB	Share
CYP	CYP in Collaboration on Acute Respiratory Distress Syndrome	PRICE SENSITIVE	11/04/17	186.84KB	Share
CYP	Appendix 3Y-Ross Macdonald		03/04/17	23.86KB	Share
CYP	Cynata Partner apceth GmbH & Co Completes Cymerus Evaluation	PRICE SENSITIVE	31/03/17	165.81KB	Share
CYP	Proactive Investor Conference Presentation		10/03/17	1.16MB	Share
CYP	CYP Advances Development of Cymerus for Treatment of Asthma	PRICE SENSITIVE	02/03/17	170.62KB	Share
CYP	Dr Paul Wotton Appointment as Chairman of Cynata		28/02/17	169.15KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	27/02/17	571.61KB	Share
CYP	Change in substantial holding		24/02/17	1MB	Share
CYP	Becoming a substantial holder		20/02/17	1.06MB	Share
CYP	Final GvHD Preclinical Report Confirms Treatment Benefit	PRICE SENSITIVE	06/02/17	175.37KB	Share
CYP	Positive Preliminary Data from Preclinical HeartAttack Study	PRICE SENSITIVE	02/02/17	169.13KB	Share
CYP	Notice Under Section 708A		30/01/17	101.69KB	Share
CYP	Information Required Under ASX Listing Rule 3.10.5A		30/01/17	105.07KB	Share
CYP	Appendix 3B-Completion of Placement		30/01/17	184.81KB	Share
CYP	Notice Under Section 708A		25/01/17	101.9KB	Share
CYP	Appendix 3B-Receipt of Funds & Issue of Shares to Fujifilm		25/01/17	220.38KB	Share
CYP	Appendix 4C - quarterly	PRICE SENSITIVE	25/01/17	97.32KB	Share
CYP	Cynata Successfully Completes Capital Raising	PRICE SENSITIVE	23/01/17	162.26KB	Share
CYP	Trading Halt	PRICE SENSITIVE	19/01/17	435.02KB	Share
CYP	Cynata & FUJIFILM Sign Strategic Partnership Agreement	PRICE SENSITIVE	19/01/17	172.15KB	Share
CYP	Proposed Fujifilm Development&Commercialisation Transaction		29/12/16	160.67KB	Share
CYP	Cynata's Clinical Study Approved in Austrralia	PRICE SENSITIVE	15/12/16	196.56KB	Share
CYP	Cynata Receives NHS HRA Approval for Clinical Study	PRICE SENSITIVE	13/12/16	196.66KB	Share
CYP	Change of Share Registry Address		09/12/16	210.65KB	Share
CYP	Cynata Files Further Patent Application	PRICE SENSITIVE	29/11/16	158.5KB	Share
CYP	Appendix 3Y x 4		17/11/16	122.66KB	Share
CYP	Appendix 3B		17/11/16	184.85KB	Share
CYP	Results of AGM		16/11/16	507.92KB	Share
CYP	AGM Presentation		16/11/16	738.73KB	Share
CYP	Cynata Receives $1.749m R&D Tax Incentive Refund	PRICE SENSITIVE	15/11/16	161.97KB	Share
CYP	Activities Report & Appendix 4C-CYP.AX	PRICE SENSITIVE	31/10/16	233.28KB	Share
CYP	Efficacy for CYP MSC Technology in Preclinical Asthma Study-CYP.AX	PRICE SENSITIVE	17/10/16	200.07KB	Share
CYP	Annual Report to Shareholders-CYP.AX		13/10/16	845.68KB	Share
CYP	Notice of Annual General Meeting/Proxy Form-CYP.AX		13/10/16	1.09MB	Share
CYP	UK Regulatory Authority Approves Cynata GvHD Clinical Trial-CYP.AX	PRICE SENSITIVE	19/09/16	217.82KB	Share
CYP	Trading Halt-CYP.AX	PRICE SENSITIVE	19/09/16	371.33KB	Share
CYP	Expiry of Unlisted Options-CYP.AX		12/09/16	160.25KB	Share
CYP	Appendix 3Y-Stewart Washer-CYP.AX		09/09/16	24.44KB	Share
CYP	Corporate Presentation-CYP.AX		07/09/16	2.01MB	Share
CYP	CYP Determines not to proceed with Regience Investment Offer-CYP.AX	PRICE SENSITIVE	05/09/16	196.78KB	Share
CYP	CYP & FUJIFILM Sign Non-Binding Terms Sheet-CYP.AX	PRICE SENSITIVE	05/09/16	166.7KB	Share
CYP	Trading Halt-CYP.AX	PRICE SENSITIVE	02/09/16	756.85KB	Share
CYP	Appendix 4G-CYP.AX		19/08/16	124.46KB	Share
CYP	Appendix 4E & Financial Statements-CYP.AX	PRICE SENSITIVE	19/08/16	915.03KB	Share
CYP	Expiry of Unlisted Options-CYP.AX		17/08/16	160.61KB	Share
CYP	Cynata Files Application to Commence Phase 1 Clinical Trial-CYP.AX	PRICE SENSITIVE	01/08/16	159.17KB	Share
CYP	Activities Report & Appendix 4C-CYP.AX	PRICE SENSITIVE	29/07/16	763.4KB	Share
CYP	Cynata Receives Investment Offer from Regience-CYP.AX	PRICE SENSITIVE	30/06/16	168.66KB	Share
CYP	Cynata Prepares for Phase 1 Clinical Trial-CYP.AX	PRICE SENSITIVE	21/06/16	180.03KB	Share
CYP	Initial Director's Interest Notice-CYP.AX		09/06/16	62.67KB	Share
CYP	Cynata Appoints Paul K Wotton Ph.D. to Board of Directors-CYP.AX		09/06/16	173.18KB	Share
CYP	Cynata Enters Agreement with apceth GmbH & Co KG-CYP.AX	PRICE SENSITIVE	09/05/16	171.7KB	Share
CYP	CYP Manufactures CT Product-Files Further Patent Application-CYP.AX	PRICE SENSITIVE	05/05/16	167.63KB	Share
CYP	Decision to Grant Patent for Cymerus MSC Technology in Japan-CYP.AX	PRICE SENSITIVE	02/05/16	160.65KB	Share
CYP	Cynata & Regience Extend Entitlement Period-CYP.AX	PRICE SENSITIVE	29/04/16	172.73KB	Share
CYP	Quarterly Activities Report & Appendix 4C-CYP.AX	PRICE SENSITIVE	29/04/16	267.54KB	Share
CYP	Compelling Results from Pre-Clinical Stem Cell Study in GvHD-CYP.AX	PRICE SENSITIVE	07/04/16	192.82KB	Share
CYP	Cynata Enters Agreement for Strategic Alliance in Japan	PRICE SENSITIVE	03/03/16	173.91KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	26/02/16	1.7MB	Share
CYP	Appendix 3B		22/02/16	179.36KB	Share
CYP	Cynata Receives $930k R&D Tax Incentive Refund	PRICE SENSITIVE	16/02/16	151.61KB	Share
CYP	Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	29/01/16	256.2KB	Share
CYP	CYP Receives Favourable Advice from UK Regulatory Authority	PRICE SENSITIVE	28/01/16	186.72KB	Share
CYP	Cynata CLI Study Published in Peer Reviewed Journal	PRICE SENSITIVE	12/01/16	183.24KB	Share
CYP	Cynata Enters Letter of Intent for a Commercial Partnership	PRICE SENSITIVE	17/12/15	165.9KB	Share
CYP	Appendix 3B		16/12/15	181.18KB	Share
CYP	Rodman & Renshaw Initiates Cynata Research Coverage		08/12/15	148.29KB	Share

CYP Cynata to Increase Exposure in Japan
09/10/17	PRICE SENSITIVE	208.86KB	Share
CYP US Patent Granted for Cynata Cymerus Technology
27/09/17	PRICE SENSITIVE	178.12KB	Share
CYP HC Wainwright & Co Updates Cynata Research Coverage
11/09/17		158.18KB	Share
CYP Cynata to Present at Rodman & Renshaw Investor Conference
05/09/17		162.42KB	Share
CYP Health Canada Meeting Advances CYP Global Development Plans
31/08/17	PRICE SENSITIVE	165.95KB	Share
CYP Appendix 4G
24/08/17		174.24KB	Share
CYP Appendix 4E & Financial Statements
24/08/17	PRICE SENSITIVE	1005.24KB	Share
CYP Positive Data from CYP MSCs in 2nd Preclinical Asthma Study
23/08/17	PRICE SENSITIVE	226.69KB	Share
CYP Appendix 3B
07/08/17		266.57KB	Share
CYP June 2017 Quarterly Report
28/07/17	PRICE SENSITIVE	283.27KB	Share
CYP NDF's Stuart Roberts Initiates Cynata Research Coverage
24/07/17		157.69KB	Share
CYP FDA Meeting Provides Clear Path for US Development Plans
05/07/17	PRICE SENSITIVE	168.09KB	Share
CYP Change of Address
04/07/17		117.52KB	Share
CYP Cynata Therapeutics GvHD Clinical Trial & Corporate Progress
27/06/17	PRICE SENSITIVE	177.28KB	Share
CYP CYP MSC Data in Asthma Model Published in Sceintific Journal
22/06/17	PRICE SENSITIVE	230.33KB	Share
CYP Cynata Files New Patent Application for Cymerus in Oncology
20/06/17	PRICE SENSITIVE	186.95KB	Share
CYP United States Patent for Core Cynata Technology
19/06/17	PRICE SENSITIVE	179.58KB	Share
CYP Van Leeuwenhoeck Institute Initiates CYP Research Coverage
07/06/17		159.1KB	Share
CYP Appendix 3Y-Peter Webse
02/06/17		24.34KB	Share
CYP Appendix 3Y Lodged 26 May 2017-Date Correction
02/06/17		24.08KB	Share
CYP Cynata Investor Presentation May 2017
29/05/17		874.26KB	Share
CYP Appendix 3Y-Paul Wotton
26/05/17		24.02KB	Share
CYP Appendix 3Y-John Chiplin
17/05/17		23.36KB	Share
CYP Treatment Commences in Cynata's World First Clinical Trial
16/05/17	PRICE SENSITIVE	209.68KB	Share
CYP Trading Halt
15/05/17	PRICE SENSITIVE	191.19KB	Share
CYP Interview with UK Chief Investigator in CYP Clinical Trial
10/05/17		163.88KB	Share
CYP Shaw & Partners Initiates Cynata Research Coverage
08/05/17		155.98KB	Share
CYP Appendix 3Y-Paul Wotton
08/05/17		24.13KB	Share
CYP Cyanta Presentation & Webcast
04/05/17		163.08KB	Share
CYP Appendix 3Y-Stewart Washer
03/05/17		24.51KB	Share
CYP March 2017 Quarterly Report
26/04/17	PRICE SENSITIVE	306.13KB	Share
CYP Cynata Advances to Pre-IND Meeting with US FDA
19/04/17	PRICE SENSITIVE	168.35KB	Share
CYP CYP Files for New Patent for Oncology Applications
12/04/17	PRICE SENSITIVE	163.15KB	Share
CYP CYP in Collaboration on Acute Respiratory Distress Syndrome
11/04/17	PRICE SENSITIVE	186.84KB	Share
CYP Appendix 3Y-Ross Macdonald
03/04/17		23.86KB	Share
CYP Cynata Partner apceth GmbH & Co Completes Cymerus Evaluation
31/03/17	PRICE SENSITIVE	165.81KB	Share
CYP Proactive Investor Conference Presentation
10/03/17		1.16MB	Share
CYP CYP Advances Development of Cymerus for Treatment of Asthma
02/03/17	PRICE SENSITIVE	170.62KB	Share
CYP Dr Paul Wotton Appointment as Chairman of Cynata
28/02/17		169.15KB	Share
CYP Appendix 4D & Half-Year Financial Statements
27/02/17	PRICE SENSITIVE	571.61KB	Share
CYP Change in substantial holding
24/02/17		1MB	Share
CYP Becoming a substantial holder
20/02/17		1.06MB	Share
CYP Final GvHD Preclinical Report Confirms Treatment Benefit
06/02/17	PRICE SENSITIVE	175.37KB	Share
CYP Positive Preliminary Data from Preclinical HeartAttack Study
02/02/17	PRICE SENSITIVE	169.13KB	Share
CYP Notice Under Section 708A
30/01/17		101.69KB	Share
CYP Information Required Under ASX Listing Rule 3.10.5A
30/01/17		105.07KB	Share
CYP Appendix 3B-Completion of Placement
30/01/17		184.81KB	Share
CYP Notice Under Section 708A
25/01/17		101.9KB	Share
CYP Appendix 3B-Receipt of Funds & Issue of Shares to Fujifilm
25/01/17		220.38KB	Share
CYP Appendix 4C - quarterly
25/01/17	PRICE SENSITIVE	97.32KB	Share
CYP Cynata Successfully Completes Capital Raising
23/01/17	PRICE SENSITIVE	162.26KB	Share
CYP Trading Halt
19/01/17	PRICE SENSITIVE	435.02KB	Share
CYP Cynata & FUJIFILM Sign Strategic Partnership Agreement
19/01/17	PRICE SENSITIVE	172.15KB	Share
CYP Proposed Fujifilm Development&Commercialisation Transaction
29/12/16		160.67KB	Share
CYP Cynata's Clinical Study Approved in Austrralia
15/12/16	PRICE SENSITIVE	196.56KB	Share
CYP Cynata Receives NHS HRA Approval for Clinical Study
13/12/16	PRICE SENSITIVE	196.66KB	Share
CYP Change of Share Registry Address
09/12/16		210.65KB	Share
CYP Cynata Files Further Patent Application
29/11/16	PRICE SENSITIVE	158.5KB	Share
CYP Appendix 3Y x 4
17/11/16		122.66KB	Share
CYP Appendix 3B
17/11/16		184.85KB	Share
CYP Results of AGM
16/11/16		507.92KB	Share
CYP AGM Presentation
16/11/16		738.73KB	Share
CYP Cynata Receives $1.749m R&D Tax Incentive Refund
15/11/16	PRICE SENSITIVE	161.97KB	Share
CYP Activities Report & Appendix 4C-CYP.AX
31/10/16	PRICE SENSITIVE	233.28KB	Share
CYP Efficacy for CYP MSC Technology in Preclinical Asthma Study-CYP.AX
17/10/16	PRICE SENSITIVE	200.07KB	Share
CYP Annual Report to Shareholders-CYP.AX
13/10/16		845.68KB	Share
CYP Notice of Annual General Meeting/Proxy Form-CYP.AX
13/10/16		1.09MB	Share
CYP UK Regulatory Authority Approves Cynata GvHD Clinical Trial-CYP.AX
19/09/16	PRICE SENSITIVE	217.82KB	Share
CYP Trading Halt-CYP.AX
19/09/16	PRICE SENSITIVE	371.33KB	Share
CYP Expiry of Unlisted Options-CYP.AX
12/09/16		160.25KB	Share
CYP Appendix 3Y-Stewart Washer-CYP.AX
09/09/16		24.44KB	Share
CYP Corporate Presentation-CYP.AX
07/09/16		2.01MB	Share
CYP CYP Determines not to proceed with Regience Investment Offer-CYP.AX
05/09/16	PRICE SENSITIVE	196.78KB	Share
CYP CYP & FUJIFILM Sign Non-Binding Terms Sheet-CYP.AX
05/09/16	PRICE SENSITIVE	166.7KB	Share
CYP Trading Halt-CYP.AX
02/09/16	PRICE SENSITIVE	756.85KB	Share
CYP Appendix 4G-CYP.AX
19/08/16		124.46KB	Share
CYP Appendix 4E & Financial Statements-CYP.AX
19/08/16	PRICE SENSITIVE	915.03KB	Share
CYP Expiry of Unlisted Options-CYP.AX
17/08/16		160.61KB	Share
CYP Cynata Files Application to Commence Phase 1 Clinical Trial-CYP.AX
01/08/16	PRICE SENSITIVE	159.17KB	Share
CYP Activities Report & Appendix 4C-CYP.AX
29/07/16	PRICE SENSITIVE	763.4KB	Share
CYP Cynata Receives Investment Offer from Regience-CYP.AX
30/06/16	PRICE SENSITIVE	168.66KB	Share
CYP Cynata Prepares for Phase 1 Clinical Trial-CYP.AX
21/06/16	PRICE SENSITIVE	180.03KB	Share
CYP Initial Director's Interest Notice-CYP.AX
09/06/16		62.67KB	Share
CYP Cynata Appoints Paul K Wotton Ph.D. to Board of Directors-CYP.AX
09/06/16		173.18KB	Share
CYP Cynata Enters Agreement with apceth GmbH & Co KG-CYP.AX
09/05/16	PRICE SENSITIVE	171.7KB	Share
CYP CYP Manufactures CT Product-Files Further Patent Application-CYP.AX
05/05/16	PRICE SENSITIVE	167.63KB	Share
CYP Decision to Grant Patent for Cymerus MSC Technology in Japan-CYP.AX
02/05/16	PRICE SENSITIVE	160.65KB	Share
CYP Cynata & Regience Extend Entitlement Period-CYP.AX
29/04/16	PRICE SENSITIVE	172.73KB	Share
CYP Quarterly Activities Report & Appendix 4C-CYP.AX
29/04/16	PRICE SENSITIVE	267.54KB	Share
CYP Compelling Results from Pre-Clinical Stem Cell Study in GvHD-CYP.AX
07/04/16	PRICE SENSITIVE	192.82KB	Share
CYP Cynata Enters Agreement for Strategic Alliance in Japan
03/03/16	PRICE SENSITIVE	173.91KB	Share
CYP Appendix 4D & Half-Year Financial Statements
26/02/16	PRICE SENSITIVE	1.7MB	Share
CYP Appendix 3B
22/02/16		179.36KB	Share
CYP Cynata Receives $930k R&D Tax Incentive Refund
16/02/16	PRICE SENSITIVE	151.61KB	Share
CYP Quarterly Activities Report & Appendix 4C
29/01/16	PRICE SENSITIVE	256.2KB	Share
CYP CYP Receives Favourable Advice from UK Regulatory Authority
28/01/16	PRICE SENSITIVE	186.72KB	Share
CYP Cynata CLI Study Published in Peer Reviewed Journal
12/01/16	PRICE SENSITIVE	183.24KB	Share
CYP Cynata Enters Letter of Intent for a Commercial Partnership
17/12/15	PRICE SENSITIVE	165.9KB	Share
CYP Appendix 3B
16/12/15		181.18KB	Share
CYP Rodman & Renshaw Initiates Cynata Research Coverage
08/12/15		148.29KB	Share

REFRESH

First 3 4 5 6 7

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 18.5¢		Change 0.015(8.82%)		Mkt cap ! $41.80M

Open	High	Low	Value	Volume
17.5¢	18.5¢	17.0¢	$21.36K	121.2K

Buyers (Bids)

No.	Vol.	Price($)
1	15599	18.0¢

Sellers (Offers)

Price($)	Vol.	No.
18.5¢	27303	2

View Market Depth

No.	Vol.	Price($)
3	50585	0.170
4	141820	0.165
7	235931	0.160
7	385725	0.155
5	136379	0.150

Price($)	Vol.	No.
0.185	27303	2
0.190	75000	1
0.195	6764	2
0.200	55400	2
0.205	6245	1

Last trade - 16.10pm 08/08/2025 (20 minute delay)

CYP (ASX) Chart

CYNATA THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories